GlassScriptPhysician profile
Melissa Cave
NPI 1912217423
$2,979.79
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $764 · 2022: $767 · 2023: $1,177 · 2024: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,448.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $753.45 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $362.83 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $231.71 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.33 | 2021-2023 | Xifaxan, Trulance |
| Lilly USA, LLC | $181.18 | 2021-2024 | Mounjaro, Jardiance |
| Dexcom, INC. | $175.54 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $140.13 | 2021-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $136.63 | 2022-2024 | |
| Amgen INC. | $102.89 | 2022-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.73 | 2021-2023 | Jardiance |
| Amarin Pharma, INC. | $78.56 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $69.62 | 2021-2023 | Farxiga |
| Pfizer INC. | $59.94 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $45.73 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $45.15 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $39.61 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $37.80 | 2021-2023 | Dificid |
| Biohaven Pharmaceuticals, INC. | $36.17 | 2021 | |
| Sanofi-Aventis U.S. LLC | $34.28 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $26.90 | 2021 | |
| Axsome Therapeutics, INC. | $26.36 | 2023 | Sunosi |
| Lundbeck LLC | $25.28 | 2023 | Rexulti |
| Esperion Therapeutics, INC. | $19.84 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.04 | 2022 | |
| Amryt Pharma Holdings LTD | $15.94 | 2023 | Juxtapid |
| Glaxosmithkline, LLC. | $15.63 | 2023 | Arexvy, Shingrix |
| Exact Sciences Corporation | $12.82 | 2023 | Cologuard Collection Kit |
| Mannkind Corporation | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Cave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.